Prodrugs for the treatment of neglected diseases
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.3390/molecules13030616 http://hdl.handle.net/11449/7916 |
Resumo: | Recently, World Health Organization ( WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [ 3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease ( American trypanosomiasis), sleeping sickness ( African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis. |
id |
UNSP_08c231a740873d8b46074d2de2c09be5 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/7916 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Prodrugs for the treatment of neglected diseasestropical neglected diseasesprodrug designAmerican trypanosomisasisAfrican trypanosomiasismalariasickle cell diseasetuberculosisleishmaniasisschistosomiasisRecently, World Health Organization ( WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [ 3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease ( American trypanosomiasis), sleeping sickness ( African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.UNESP Rodovia Araraquara, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, Lapdesf Lab Desenvolvimento Farmacos, BR-14801902 São Paulo, BrazilUSP SP, Fac Ciencias Farmaceut, Dept Farm, LAPEN Lab Planejamento & Sintese Quimioterap Pote, BR-05508900 São Paulo, BrazilUNESP Rodovia Araraquara, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, Lapdesf Lab Desenvolvimento Farmacos, BR-14801902 São Paulo, BrazilMolecular Diversity Preservation IntUniversidade Estadual Paulista (Unesp)Universidade de São Paulo (USP)Chin, Chung Man [UNESP]Ferreira, Elizabeth IgneSantos, Jean Leandro [UNESP]Giarolla, JeanineRando, Daniela GoncalesAlmeida, Adelia Emilia de [UNESP]Bosquesi, Priscila Longhin [UNESP]Menegon, Renato Farina [UNESP]Blau, Lorena [UNESP]2014-05-20T13:25:01Z2014-05-20T13:25:01Z2008-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article616-677application/pdfhttp://dx.doi.org/10.3390/molecules13030616Molecules. Basel: Molecular Diversity Preservation Int, v. 13, n. 3, p. 616-677, 2008.1420-3049http://hdl.handle.net/11449/791610.3390/molecules13030616WOS:000254464700011WOS000254464700011.pdf97343336079754130000-0003-4141-0455Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengMolecules3.0980,855info:eu-repo/semantics/openAccess2024-06-24T13:46:23Zoai:repositorio.unesp.br:11449/7916Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T22:02:52.407990Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Prodrugs for the treatment of neglected diseases |
title |
Prodrugs for the treatment of neglected diseases |
spellingShingle |
Prodrugs for the treatment of neglected diseases Chin, Chung Man [UNESP] tropical neglected diseases prodrug design American trypanosomisasis African trypanosomiasis malaria sickle cell disease tuberculosis leishmaniasis schistosomiasis |
title_short |
Prodrugs for the treatment of neglected diseases |
title_full |
Prodrugs for the treatment of neglected diseases |
title_fullStr |
Prodrugs for the treatment of neglected diseases |
title_full_unstemmed |
Prodrugs for the treatment of neglected diseases |
title_sort |
Prodrugs for the treatment of neglected diseases |
author |
Chin, Chung Man [UNESP] |
author_facet |
Chin, Chung Man [UNESP] Ferreira, Elizabeth Igne Santos, Jean Leandro [UNESP] Giarolla, Jeanine Rando, Daniela Goncales Almeida, Adelia Emilia de [UNESP] Bosquesi, Priscila Longhin [UNESP] Menegon, Renato Farina [UNESP] Blau, Lorena [UNESP] |
author_role |
author |
author2 |
Ferreira, Elizabeth Igne Santos, Jean Leandro [UNESP] Giarolla, Jeanine Rando, Daniela Goncales Almeida, Adelia Emilia de [UNESP] Bosquesi, Priscila Longhin [UNESP] Menegon, Renato Farina [UNESP] Blau, Lorena [UNESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Universidade de São Paulo (USP) |
dc.contributor.author.fl_str_mv |
Chin, Chung Man [UNESP] Ferreira, Elizabeth Igne Santos, Jean Leandro [UNESP] Giarolla, Jeanine Rando, Daniela Goncales Almeida, Adelia Emilia de [UNESP] Bosquesi, Priscila Longhin [UNESP] Menegon, Renato Farina [UNESP] Blau, Lorena [UNESP] |
dc.subject.por.fl_str_mv |
tropical neglected diseases prodrug design American trypanosomisasis African trypanosomiasis malaria sickle cell disease tuberculosis leishmaniasis schistosomiasis |
topic |
tropical neglected diseases prodrug design American trypanosomisasis African trypanosomiasis malaria sickle cell disease tuberculosis leishmaniasis schistosomiasis |
description |
Recently, World Health Organization ( WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [ 3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease ( American trypanosomiasis), sleeping sickness ( African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis. |
publishDate |
2008 |
dc.date.none.fl_str_mv |
2008-03-01 2014-05-20T13:25:01Z 2014-05-20T13:25:01Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3390/molecules13030616 Molecules. Basel: Molecular Diversity Preservation Int, v. 13, n. 3, p. 616-677, 2008. 1420-3049 http://hdl.handle.net/11449/7916 10.3390/molecules13030616 WOS:000254464700011 WOS000254464700011.pdf 9734333607975413 0000-0003-4141-0455 |
url |
http://dx.doi.org/10.3390/molecules13030616 http://hdl.handle.net/11449/7916 |
identifier_str_mv |
Molecules. Basel: Molecular Diversity Preservation Int, v. 13, n. 3, p. 616-677, 2008. 1420-3049 10.3390/molecules13030616 WOS:000254464700011 WOS000254464700011.pdf 9734333607975413 0000-0003-4141-0455 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Molecules 3.098 0,855 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
616-677 application/pdf |
dc.publisher.none.fl_str_mv |
Molecular Diversity Preservation Int |
publisher.none.fl_str_mv |
Molecular Diversity Preservation Int |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129387094081536 |